<p>Jacobio Pharmaceuticals Group Co. Ltd. has appointed Dr. Andrea Wang-Gillam as Co-Chief Executive Officer. Dr. Wang-Gillam, who previously served as Chief Medical Officer and Senior Vice President, will focus on business development and operational management in global markets. Dr. Wang Yinxiang will remain as Chairman and Chief Executive Officer. The new Co-CEO structure is intended to strengthen the company’s capabilities in global drug research, development, and commercialization. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jacobio Pharmaceuticals Group Co. Ltd. published the original content used to generate this news brief on November 13, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here</p>

01167

<p>Jacobio Pharmaceuticals Group Co. Ltd. has appointed Dr. Andrea Wang-Gillam as Co-CEO, focusing on business development and operational management in global markets. Dr. Wang Yinxiang continues as Chairman and CEO. This new Co-CEO structure aims to enhance the company's capabilities in global drug research, development, and commercialization.</p>

Jacobio Pharmaceuticals Appoints Dr. Andrea Wang-Gillam as Co-CEO